Nycomed ‘s dermatology business, Nycomed US , will become an independent corporation following Takeda Pharmaceutical’s acquisition of its parent company.

Nycomed US will continue to be owned by the Swiss holding companies that had previously held Nycomed, and the company will retain its headquarters in Melville, New York.

Its Fougera and PharmaDerm divisions will also remain.

The new ownership structure will become effective following closure of Takeda’s acquisition, expected to occur in the third quarter of 2011, although management and day-to-day operations will remain unchanged.

Nycomed US CEO Steve Andrzejewski said, “Although Nycomed US made a significant contribution to Nycomed on a global basis, our product portfolio was outside Nycomed’s stated strategy and our investors believe we have a highly promising future under this separate ownership structure.”

Nycomed US employs more than 700 people and has revenue approaching $500m from its range of skin disease treatments.